Ogivri (trastuzumab-dkst) is a biosimilar to Herceptin (trastuzumab).
A biosimilar is a biological product that is FDA-approved and highly similar to a biologic already FDA-approved with no clinically meaningful differences in terms of safety and effectiveness from the reference product.
What Are Biosimilars? Top Facts You May Not Know
Ogivri and Herceptin are both used for the treatment of patients with HER2+ breast cancer or HER2-overexpressing metastatic stomach cancer (metastatic gastric or gastroesophageal junction adenocarcinoma).
Ogivri has not been approved as an interchangeable biosimilar, meaning the pharmacist cannot substitute Ogivri for Herceptin without consulting the prescriber.
Ogivri was the first approved biosimilar to Herceptin.
Herceptin (trastuzumab) Biosimilars
- Ogivri (trastuzumab-dkst)
- Herzuma (trastuzumab-pkrb)
- Ontruzant (trastuzumab-dttb)
- Trazimera (trastuzumab-qyyp)
- Kanjinti (trastuzumab-anns)